Gallo I, Ruiz B, Duran C M
Thorac Cardiovasc Surg. 1983 Oct;31(5):277-81. doi: 10.1055/s-2007-1021996.
All patients undergoing a heart valve replacement with a glutaraldehyde Carpentier-Edwards xenograft from April 1978 through December 1980 were reviewed. This analysis included 189 patients: 117 having a mitral valve replacement (MVR), 45 having an aortic valve replacement (AVR), and 27 having mitral and aortic valve replacements (MAVR). Out of 174 patients discharged from the hospital, one was lost to follow-up and is excluded from the analysis. There were 11 late deaths, which represent an incidence of 1.89% per patient-year for the MVR (6/106), 0.83% per patient-year for the AVR (1/41), and 5.83% per patient-year for the MAVR (4/26). There were 6 instances of infective endocarditis (4 MVR, 2 MAVR), which represent a linearized incidence o 1.26% and 2.91% per patient-year for the MVR and MAVR respectively. All were successfully treated with medication. There were 10 thromboembolic events in 7 patients (6 MVR had 9 events and 1 AVR had 1 event). This represents a linearized incidence of 2.84% and 0.83% per patient-year for MVR and AVR, respectively. Primary tissue failure was observed in 3 patients (2 MVR, 1 MAVR), who required reoperation for explantation of the mitral valves. This represents an overall linearized incidence of mitral failures of 0.78% per patient-year. The probability of being free from primary tissue failure is 95.9 +/- 4.9% for all mitral prostheses at 4.5 years of follow-up. These current results indicate that the Carpentier-Edwards porcine xenograft valve can be considered as a valid alternative for heart valve replacement.
对1978年4月至1980年12月期间所有接受戊二醛处理的Carpentier-Edwards异种生物心脏瓣膜置换术的患者进行了回顾性研究。该分析纳入了189例患者：117例行二尖瓣置换术（MVR），45例行主动脉瓣置换术（AVR），27例行二尖瓣和主动脉瓣置换术（MAVR）。174例出院患者中，1例失访，故排除在分析之外。共有11例晚期死亡，MVR患者的年发生率为1.89%（6/106），AVR患者为0.83%（1/41），MAVR患者为5.83%（4/26）。有6例感染性心内膜炎（4例MVR，2例MAVR），MVR和MAVR患者的线性化年发生率分别为1.26%和2.91%。所有患者均通过药物治疗成功治愈。7例患者发生了10次血栓栓塞事件（6例MVR患者发生9次，1例AVR患者发生1次）。MVR和AVR患者的线性化年发生率分别为2.84%和0.83%。3例患者（2例MVR，1例MAVR）出现原发性组织衰竭，需要再次手术取出二尖瓣。二尖瓣衰竭的总体线性化年发生率为0.78%。在4.5年的随访中，所有二尖瓣假体无原发性组织衰竭的概率为95.9±4.9%。目前的这些结果表明，Carpentier-Edwards猪异种生物瓣膜可被视为心脏瓣膜置换的有效替代方案。
